BOHUI

Beijing Bohui Innovation Biotechnology Group Co., Ltd. was established in 2001 and has now become a high-tech biomedical enterprise that integrates research and development, production, sales, and after-sales services. The company was listed on the ChiNext Board of the Shenzhen Stock Exchange in May 2012 (Stock Code: 300318). BOHUI possesses strong independent R&D capabilities and has established a professional R&D team. Through continuous technological innovation, it has developed five major technology platforms: molecular diagnostics, immunoassays, atomic absorption, atomic fluorescence, and mass spectrometry. It has successfully industrialized products from these technology platforms. Its human trace element detection system is widely used in over 7,000 hospitals across China, with an annual testing volume of up to 22 million people. The company’s fully automated nucleic acid detection system, developed using advanced microfluidic chip technology, is known as a "lab-on-a-chip" and serves numerous medical and health institutions. BOHUI has undertaken several major scientific and technological industrialization projects, such as the National Twelfth Five-Year Plan Major Scientific Instrument Project “Micropump-Driven Nucleic Acid Micro Total Analysis System,” the Thirteenth Five-Year Plan Major Scientific Instrument Project “Development and Application of New Atomic Fluorescence Spectrometer,” and the National 863 Project “Development of Medical ICP-MS Human Trace Element Analysis System.” It has also been approved to establish high-end technology R&D platforms and talent cultivation bases such as the “Beijing Engineering Laboratory for Microfluidic Molecular Detection Technology” and the “Postdoctoral Research Station.” In 2015, BOHUI fully acquired Advion Inc. in the United States, focusing on the application of mass spectrometry analysis in the life sciences field, providing customers with excellent mass spectrometry products and user experience. The company acquired Hebei Daan Pharmaceutical Co., Ltd. and Guangdong Weilun Biological Pharmaceutical Co., Ltd., entering the biopharmaceuticals field and further improving its health ecosystem industry chain. BOHUI extensively collaborates with universities and research institutions on R&D, achieving deep integration of industry, academia, and research, accelerating the transformation of scientific and technological achievements, and continuously striving to improve public health levels.